p53 Expression in neurofibroma and malignant peripheral nerve sheath tumor: An immunohistochemical study of sporadic and NF1-associated tumors

Kevin C. Halling, Bernd W. Scheithauer, Amy C. Halling, Antonio G. Nascimento, Steven C. Ziesmer, Patrick C. Roche, Peter C. Wollan

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Malignant peripheral nerve sheath tumors (MPNST) are highly malignant sarcomas arising either de novo or in transition from neurofibroma. Although relatively little is known of the molecular genetic alterations that underlie their formation, recent DNA sequencing studies have demonstrated the presence of p53 mutations in some MPNST. This tumor-suppressor gene has been implicated in the progression of a variety of human malignancies, including sarcomas. Employing the anti-p53 monoclonal antibody Do-7, this retrospective immunohistochemical study of p53 gene overexpression in MPNST found reactivity to be present in 68% and to be significant in degree in 57%. In contrast, although some degree of p53 overexpression was present in 48% of neurofibromas, none stained strongly and only 1 of the 27 (4%), a cellular example, showed significant staining. No difference in the frequency or degree of p53 staining was noted between MPNSTs from patients with or without neurofibromatosis 1. The observed overexpression of the gene product, possibly the reflection of a p53 gene mutation, suggests a ride for p53 in the progression of neurofibroma to MPNST. Although the prognostic of p53 overexpression in MPNST remains to be confirmed, in the present series immunopositive tumors were associated with a shorter median patient survival (18 months) than were tumors showing no reactivity (82 months) (P = .02).

Original languageEnglish (US)
Pages (from-to)282-288
Number of pages7
JournalAmerican Journal of Clinical Pathology
Volume106
Issue number3
StatePublished - Sep 1996

Fingerprint

Neurofibroma
Neurilemmoma
Neoplasms
p53 Genes
Sarcoma
Staining and Labeling
Mutation
Neurofibromatosis 1
Tumor Suppressor Genes
DNA Sequence Analysis
Molecular Biology
Retrospective Studies
Monoclonal Antibodies
Survival
Genes

Keywords

  • Malignant peripheral nerve sheath tumor
  • Neurofibroma
  • p53
  • Prognosis
  • Tumor-suppressor gene

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Halling, K. C., Scheithauer, B. W., Halling, A. C., Nascimento, A. G., Ziesmer, S. C., Roche, P. C., & Wollan, P. C. (1996). p53 Expression in neurofibroma and malignant peripheral nerve sheath tumor: An immunohistochemical study of sporadic and NF1-associated tumors. American Journal of Clinical Pathology, 106(3), 282-288.

p53 Expression in neurofibroma and malignant peripheral nerve sheath tumor : An immunohistochemical study of sporadic and NF1-associated tumors. / Halling, Kevin C.; Scheithauer, Bernd W.; Halling, Amy C.; Nascimento, Antonio G.; Ziesmer, Steven C.; Roche, Patrick C.; Wollan, Peter C.

In: American Journal of Clinical Pathology, Vol. 106, No. 3, 09.1996, p. 282-288.

Research output: Contribution to journalArticle

Halling, KC, Scheithauer, BW, Halling, AC, Nascimento, AG, Ziesmer, SC, Roche, PC & Wollan, PC 1996, 'p53 Expression in neurofibroma and malignant peripheral nerve sheath tumor: An immunohistochemical study of sporadic and NF1-associated tumors', American Journal of Clinical Pathology, vol. 106, no. 3, pp. 282-288.
Halling, Kevin C. ; Scheithauer, Bernd W. ; Halling, Amy C. ; Nascimento, Antonio G. ; Ziesmer, Steven C. ; Roche, Patrick C. ; Wollan, Peter C. / p53 Expression in neurofibroma and malignant peripheral nerve sheath tumor : An immunohistochemical study of sporadic and NF1-associated tumors. In: American Journal of Clinical Pathology. 1996 ; Vol. 106, No. 3. pp. 282-288.
@article{85b387734a3a47f0b84333ee5da8039a,
title = "p53 Expression in neurofibroma and malignant peripheral nerve sheath tumor: An immunohistochemical study of sporadic and NF1-associated tumors",
abstract = "Malignant peripheral nerve sheath tumors (MPNST) are highly malignant sarcomas arising either de novo or in transition from neurofibroma. Although relatively little is known of the molecular genetic alterations that underlie their formation, recent DNA sequencing studies have demonstrated the presence of p53 mutations in some MPNST. This tumor-suppressor gene has been implicated in the progression of a variety of human malignancies, including sarcomas. Employing the anti-p53 monoclonal antibody Do-7, this retrospective immunohistochemical study of p53 gene overexpression in MPNST found reactivity to be present in 68{\%} and to be significant in degree in 57{\%}. In contrast, although some degree of p53 overexpression was present in 48{\%} of neurofibromas, none stained strongly and only 1 of the 27 (4{\%}), a cellular example, showed significant staining. No difference in the frequency or degree of p53 staining was noted between MPNSTs from patients with or without neurofibromatosis 1. The observed overexpression of the gene product, possibly the reflection of a p53 gene mutation, suggests a ride for p53 in the progression of neurofibroma to MPNST. Although the prognostic of p53 overexpression in MPNST remains to be confirmed, in the present series immunopositive tumors were associated with a shorter median patient survival (18 months) than were tumors showing no reactivity (82 months) (P = .02).",
keywords = "Malignant peripheral nerve sheath tumor, Neurofibroma, p53, Prognosis, Tumor-suppressor gene",
author = "Halling, {Kevin C.} and Scheithauer, {Bernd W.} and Halling, {Amy C.} and Nascimento, {Antonio G.} and Ziesmer, {Steven C.} and Roche, {Patrick C.} and Wollan, {Peter C.}",
year = "1996",
month = "9",
language = "English (US)",
volume = "106",
pages = "282--288",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

TY - JOUR

T1 - p53 Expression in neurofibroma and malignant peripheral nerve sheath tumor

T2 - An immunohistochemical study of sporadic and NF1-associated tumors

AU - Halling, Kevin C.

AU - Scheithauer, Bernd W.

AU - Halling, Amy C.

AU - Nascimento, Antonio G.

AU - Ziesmer, Steven C.

AU - Roche, Patrick C.

AU - Wollan, Peter C.

PY - 1996/9

Y1 - 1996/9

N2 - Malignant peripheral nerve sheath tumors (MPNST) are highly malignant sarcomas arising either de novo or in transition from neurofibroma. Although relatively little is known of the molecular genetic alterations that underlie their formation, recent DNA sequencing studies have demonstrated the presence of p53 mutations in some MPNST. This tumor-suppressor gene has been implicated in the progression of a variety of human malignancies, including sarcomas. Employing the anti-p53 monoclonal antibody Do-7, this retrospective immunohistochemical study of p53 gene overexpression in MPNST found reactivity to be present in 68% and to be significant in degree in 57%. In contrast, although some degree of p53 overexpression was present in 48% of neurofibromas, none stained strongly and only 1 of the 27 (4%), a cellular example, showed significant staining. No difference in the frequency or degree of p53 staining was noted between MPNSTs from patients with or without neurofibromatosis 1. The observed overexpression of the gene product, possibly the reflection of a p53 gene mutation, suggests a ride for p53 in the progression of neurofibroma to MPNST. Although the prognostic of p53 overexpression in MPNST remains to be confirmed, in the present series immunopositive tumors were associated with a shorter median patient survival (18 months) than were tumors showing no reactivity (82 months) (P = .02).

AB - Malignant peripheral nerve sheath tumors (MPNST) are highly malignant sarcomas arising either de novo or in transition from neurofibroma. Although relatively little is known of the molecular genetic alterations that underlie their formation, recent DNA sequencing studies have demonstrated the presence of p53 mutations in some MPNST. This tumor-suppressor gene has been implicated in the progression of a variety of human malignancies, including sarcomas. Employing the anti-p53 monoclonal antibody Do-7, this retrospective immunohistochemical study of p53 gene overexpression in MPNST found reactivity to be present in 68% and to be significant in degree in 57%. In contrast, although some degree of p53 overexpression was present in 48% of neurofibromas, none stained strongly and only 1 of the 27 (4%), a cellular example, showed significant staining. No difference in the frequency or degree of p53 staining was noted between MPNSTs from patients with or without neurofibromatosis 1. The observed overexpression of the gene product, possibly the reflection of a p53 gene mutation, suggests a ride for p53 in the progression of neurofibroma to MPNST. Although the prognostic of p53 overexpression in MPNST remains to be confirmed, in the present series immunopositive tumors were associated with a shorter median patient survival (18 months) than were tumors showing no reactivity (82 months) (P = .02).

KW - Malignant peripheral nerve sheath tumor

KW - Neurofibroma

KW - p53

KW - Prognosis

KW - Tumor-suppressor gene

UR - http://www.scopus.com/inward/record.url?scp=0029781715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029781715&partnerID=8YFLogxK

M3 - Article

C2 - 8816583

AN - SCOPUS:0029781715

VL - 106

SP - 282

EP - 288

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 3

ER -